(Q41925058)

14 October 2017

title

Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy (English)

1 reference

14 October 2017

Brewer GJ

1

1 reference

14 October 2017

Johnson VD

2

1 reference

14 October 2017

Dick RD

3

1 reference

14 October 2017

Hedera P

4

1 reference

14 October 2017

Fink JK

5

1 reference

14 October 2017

Kluin KJ

6

1 reference

14 October 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

14 October 2017

1 reference

14 October 2017

volume

31

1 reference

14 October 2017

issue

2

1 reference

14 October 2017

page(s)

364-370

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

14 October 2017

1 reference

7 January 2021

The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Studies on copper metabolism. XIV. Radioactive copper studies in normal subjects and in patients with hepatolenticular degeneration

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Defective biliary excretion of copper in Wilson's disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Abnormalities of the physiology of copper in Wilson's disease. 3. The excretion of copper

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Biliary excretion of copper in Wilson's disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Penicillamine, a new oral therapy for Wilson's disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Oral zinc therapy for Wilson's disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with zinc XII: dose regimen requirements

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Treatment of Wilson's disease with zinc: XV long-term follow-up studies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Oral zinc in Wilson's disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Pregnancy in Penicillamine-Treated Patients with Wilson's Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Hemolytic Anemia in Wilson's Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Identification of Subgroups of Euthyroid Graves's Ophthalmopathy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Teratogen update: penicillamine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Initial therapy of patients with Wilson's disease with tetrathiomolybdate

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Wilson's disease treated with trientine during pregnancy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Drug-induced copper deficiency: a model for copper deficiency teratogenicity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310216

7 January 2021

Identifiers

DOI

10.1002/HEP.510310216

1 reference

14 October 2017

1 reference